Alpha Tau Medical Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DRTS Nasdaq 2836 www.alphatau.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alpha Tau Medical Ltd.

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead - Jan 29th, 2026 7:00 am
New Strong Sell Stocks for January 27th - Jan 27th, 2026 2:02 am
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event - Jan 23rd, 2026 12:50 pm
New Strong Sell Stocks for January 20th - Jan 20th, 2026 7:12 am
Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer - Jan 20th, 2026 7:00 am
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study - Jan 6th, 2026 7:00 am
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) - Jan 5th, 2026 7:00 am
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference - Dec 18th, 2025 7:00 am
Sidoti Events, LLC's Year-End Virtual Investor Conference - Dec 9th, 2025 10:48 am
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University - Dec 9th, 2025 7:00 am
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium - Dec 4th, 2025 7:00 am
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer - Dec 2nd, 2025 7:00 am
Alpha Tau to Participate in December Investor Conferences - Dec 1st, 2025 7:00 am
ORMP: Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan Adopted - Nov 24th, 2025 6:26 am
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 20th, 2025 2:05 pm
Alpha Tau to Participate at Jefferies Global Healthcare Conference in London - Nov 11th, 2025 6:30 am
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness - Oct 21st, 2025 6:30 am
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial - Sep 2nd, 2025 6:30 am
Alpha Tau to Participate in Five September Investor Conferences - Aug 27th, 2025 6:30 am
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 11th, 2025 2:02 pm